Canopy Growth Corporation
Canopy Growth Corporation (CGC) Stock Competitors & Peer Comparison
See (CGC) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CGC | $1.44 | +13.39% | 345.3M | -0.48 | -$3.03 | N/A |
| ZTS | $155.19 | -0.91% | 68.7B | 26.69 | $5.81 | +1.25% |
| TAK | $15.07 | -2.90% | 47.6B | 51.97 | $0.29 | +3.98% |
| HLN | $9.68 | -1.43% | 43.8B | 21.49 | $0.45 | +1.82% |
| TEVA | $18.12 | -1.84% | 20.8B | -120.83 | -$0.15 | N/A |
| ITCI | $131.87 | +0.00% | 14B | -180.64 | -$0.73 | N/A |
| NBIX | $133.99 | -1.06% | 13.3B | 39.53 | $3.39 | N/A |
| VTRS | $10.55 | -0.94% | 12.3B | -3.60 | -$2.93 | +4.56% |
| RDY | $14.46 | -0.34% | 12B | 18.53 | $0.78 | +0.63% |
| CTLT | $63.48 | +0.00% | 11.5B | -27.84 | -$2.28 | N/A |
Stock Comparison
CGC vs ZTS Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ZTS has a market cap of 68.7B. Regarding current trading prices, CGC is priced at $1.44, while ZTS trades at $155.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ZTS's P/E ratio is 26.69. In terms of profitability, CGC's ROE is -0.99%, compared to ZTS's ROE of +0.53%. Regarding short-term risk, CGC is more volatile compared to ZTS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ZTS's competition here
CGC vs TAK Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TAK has a market cap of 47.6B. Regarding current trading prices, CGC is priced at $1.44, while TAK trades at $15.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TAK's P/E ratio is 51.97. In terms of profitability, CGC's ROE is -0.99%, compared to TAK's ROE of +0.02%. Regarding short-term risk, CGC is more volatile compared to TAK. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check TAK's competition here
CGC vs HLN Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, HLN has a market cap of 43.8B. Regarding current trading prices, CGC is priced at $1.44, while HLN trades at $9.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas HLN's P/E ratio is 21.49. In terms of profitability, CGC's ROE is -0.99%, compared to HLN's ROE of +0.09%. Regarding short-term risk, CGC is more volatile compared to HLN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check HLN's competition here
CGC vs TEVA Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TEVA has a market cap of 20.8B. Regarding current trading prices, CGC is priced at $1.44, while TEVA trades at $18.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TEVA's P/E ratio is -120.83. In terms of profitability, CGC's ROE is -0.99%, compared to TEVA's ROE of -0.03%. Regarding short-term risk, CGC is more volatile compared to TEVA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check TEVA's competition here
CGC vs ITCI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ITCI has a market cap of 14B. Regarding current trading prices, CGC is priced at $1.44, while ITCI trades at $131.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ITCI's P/E ratio is -180.64. In terms of profitability, CGC's ROE is -0.99%, compared to ITCI's ROE of -0.07%. Regarding short-term risk, CGC is more volatile compared to ITCI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ITCI's competition here
CGC vs NBIX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, NBIX has a market cap of 13.3B. Regarding current trading prices, CGC is priced at $1.44, while NBIX trades at $133.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas NBIX's P/E ratio is 39.53. In terms of profitability, CGC's ROE is -0.99%, compared to NBIX's ROE of +0.13%. Regarding short-term risk, CGC is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check NBIX's competition here
CGC vs VTRS Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, VTRS has a market cap of 12.3B. Regarding current trading prices, CGC is priced at $1.44, while VTRS trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas VTRS's P/E ratio is -3.60. In terms of profitability, CGC's ROE is -0.99%, compared to VTRS's ROE of -0.20%. Regarding short-term risk, CGC is more volatile compared to VTRS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check VTRS's competition here
CGC vs RDY Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, RDY has a market cap of 12B. Regarding current trading prices, CGC is priced at $1.44, while RDY trades at $14.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas RDY's P/E ratio is 18.53. In terms of profitability, CGC's ROE is -0.99%, compared to RDY's ROE of +0.17%. Regarding short-term risk, CGC is more volatile compared to RDY. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check RDY's competition here
CGC vs CTLT Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, CTLT has a market cap of 11.5B. Regarding current trading prices, CGC is priced at $1.44, while CTLT trades at $63.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas CTLT's P/E ratio is -27.84. In terms of profitability, CGC's ROE is -0.99%, compared to CTLT's ROE of -0.06%. Regarding short-term risk, CGC is more volatile compared to CTLT. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check CTLT's competition here
CGC vs ELAN Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ELAN has a market cap of 8.8B. Regarding current trading prices, CGC is priced at $1.44, while ELAN trades at $17.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ELAN's P/E ratio is 20.22. In terms of profitability, CGC's ROE is -0.99%, compared to ELAN's ROE of +0.07%. Regarding short-term risk, CGC is more volatile compared to ELAN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ELAN's competition here
CGC vs RGC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, RGC has a market cap of 6.1B. Regarding current trading prices, CGC is priced at $1.44, while RGC trades at $12.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas RGC's P/E ratio is -1228.00. In terms of profitability, CGC's ROE is -0.99%, compared to RGC's ROE of -0.50%. Regarding short-term risk, CGC is more volatile compared to RGC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check RGC's competition here
CGC vs LNTH Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, LNTH has a market cap of 3.8B. Regarding current trading prices, CGC is priced at $1.44, while LNTH trades at $56.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas LNTH's P/E ratio is 14.94. In terms of profitability, CGC's ROE is -0.99%, compared to LNTH's ROE of +0.24%. Regarding short-term risk, CGC is more volatile compared to LNTH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check LNTH's competition here
CGC vs PRGO Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, PRGO has a market cap of 3.3B. Regarding current trading prices, CGC is priced at $1.44, while PRGO trades at $23.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas PRGO's P/E ratio is -55.28. In terms of profitability, CGC's ROE is -0.99%, compared to PRGO's ROE of -0.02%. Regarding short-term risk, CGC is more volatile compared to PRGO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check PRGO's competition here
CGC vs INDV Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, INDV has a market cap of 3B. Regarding current trading prices, CGC is priced at $1.44, while INDV trades at $24.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas INDV's P/E ratio is 29.64. In terms of profitability, CGC's ROE is -0.99%, compared to INDV's ROE of -0.48%. Regarding short-term risk, CGC is more volatile compared to INDV. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check INDV's competition here
CGC vs AMRX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, AMRX has a market cap of 2.9B. Regarding current trading prices, CGC is priced at $1.44, while AMRX trades at $9.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas AMRX's P/E ratio is 928.00. In terms of profitability, CGC's ROE is -0.99%, compared to AMRX's ROE of -0.03%. Regarding short-term risk, CGC is more volatile compared to AMRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check AMRX's competition here
CGC vs HCM Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, HCM has a market cap of 2.8B. Regarding current trading prices, CGC is priced at $1.44, while HCM trades at $15.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas HCM's P/E ratio is 6.01. In terms of profitability, CGC's ROE is -0.99%, compared to HCM's ROE of +0.05%. Regarding short-term risk, CGC is more volatile compared to HCM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check HCM's competition here
CGC vs BHC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, BHC has a market cap of 2.7B. Regarding current trading prices, CGC is priced at $1.44, while BHC trades at $7.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas BHC's P/E ratio is 28.06. In terms of profitability, CGC's ROE is -0.99%, compared to BHC's ROE of -0.09%. Regarding short-term risk, CGC is more volatile compared to BHC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check BHC's competition here
CGC vs ALVO Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ALVO has a market cap of 2.5B. Regarding current trading prices, CGC is priced at $1.44, while ALVO trades at $8.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ALVO's P/E ratio is 36.17. In terms of profitability, CGC's ROE is -0.99%, compared to ALVO's ROE of -0.21%. Regarding short-term risk, CGC is more volatile compared to ALVO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ALVO's competition here
CGC vs SUPN Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SUPN has a market cap of 2.5B. Regarding current trading prices, CGC is priced at $1.44, while SUPN trades at $44.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SUPN's P/E ratio is 38.63. In terms of profitability, CGC's ROE is -0.99%, compared to SUPN's ROE of +0.06%. Regarding short-term risk, CGC is more volatile compared to SUPN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SUPN's competition here
CGC vs ALVOW Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ALVOW has a market cap of 2.4B. Regarding current trading prices, CGC is priced at $1.44, while ALVOW trades at $1.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ALVOW's P/E ratio is N/A. In terms of profitability, CGC's ROE is -0.99%, compared to ALVOW's ROE of -0.21%. Regarding short-term risk, CGC is less volatile compared to ALVOW. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check ALVOW's competition here
CGC vs DCPH Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, DCPH has a market cap of 2.2B. Regarding current trading prices, CGC is priced at $1.44, while DCPH trades at $25.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas DCPH's P/E ratio is -11.58. In terms of profitability, CGC's ROE is -0.99%, compared to DCPH's ROE of -0.56%. Regarding short-term risk, CGC is more volatile compared to DCPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check DCPH's competition here
CGC vs ANIP Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ANIP has a market cap of 2B. Regarding current trading prices, CGC is priced at $1.44, while ANIP trades at $90.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ANIP's P/E ratio is -130.90. In terms of profitability, CGC's ROE is -0.99%, compared to ANIP's ROE of -0.03%. Regarding short-term risk, CGC is more volatile compared to ANIP. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ANIP's competition here
CGC vs EMBCV Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, EMBCV has a market cap of 1.9B. Regarding current trading prices, CGC is priced at $1.44, while EMBCV trades at $33.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas EMBCV's P/E ratio is N/A. In terms of profitability, CGC's ROE is -0.99%, compared to EMBCV's ROE of +0.71%. Regarding short-term risk, CGC is less volatile compared to EMBCV. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check EMBCV's competition here
CGC vs TARO Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TARO has a market cap of 1.6B. Regarding current trading prices, CGC is priced at $1.44, while TARO trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TARO's P/E ratio is 30.05. In terms of profitability, CGC's ROE is -0.99%, compared to TARO's ROE of +0.03%. Regarding short-term risk, CGC is more volatile compared to TARO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check TARO's competition here
CGC vs BGM Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, BGM has a market cap of 1.6B. Regarding current trading prices, CGC is priced at $1.44, while BGM trades at $8.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas BGM's P/E ratio is -27.69. In terms of profitability, CGC's ROE is -0.99%, compared to BGM's ROE of -0.03%. Regarding short-term risk, CGC is more volatile compared to BGM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check BGM's competition here
CGC vs TLRY Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TLRY has a market cap of 1.5B. Regarding current trading prices, CGC is priced at $1.44, while TLRY trades at $1.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TLRY's P/E ratio is -0.57. In terms of profitability, CGC's ROE is -0.99%, compared to TLRY's ROE of -0.78%. Regarding short-term risk, CGC is less volatile compared to TLRY. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check TLRY's competition here
CGC vs AVDL Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, AVDL has a market cap of 1.4B. Regarding current trading prices, CGC is priced at $1.44, while AVDL trades at $14.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas AVDL's P/E ratio is -740.50. In terms of profitability, CGC's ROE is -0.99%, compared to AVDL's ROE of -0.04%. Regarding short-term risk, CGC is more volatile compared to AVDL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check AVDL's competition here
CGC vs AMPH Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, AMPH has a market cap of 1.4B. Regarding current trading prices, CGC is priced at $1.44, while AMPH trades at $29.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas AMPH's P/E ratio is 11.17. In terms of profitability, CGC's ROE is -0.99%, compared to AMPH's ROE of +0.18%. Regarding short-term risk, CGC is more volatile compared to AMPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check AMPH's competition here
CGC vs HROW Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, HROW has a market cap of 1.4B. Regarding current trading prices, CGC is priced at $1.44, while HROW trades at $37.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas HROW's P/E ratio is -133.43. In terms of profitability, CGC's ROE is -0.99%, compared to HROW's ROE of -0.18%. Regarding short-term risk, CGC is more volatile compared to HROW. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check HROW's competition here
CGC vs PAHC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, PAHC has a market cap of 1.3B. Regarding current trading prices, CGC is priced at $1.44, while PAHC trades at $31.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas PAHC's P/E ratio is 40.95. In terms of profitability, CGC's ROE is -0.99%, compared to PAHC's ROE of +0.12%. Regarding short-term risk, CGC is more volatile compared to PAHC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check PAHC's competition here
CGC vs EVO Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, EVO has a market cap of 1.3B. Regarding current trading prices, CGC is priced at $1.44, while EVO trades at $3.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas EVO's P/E ratio is -7.00. In terms of profitability, CGC's ROE is -0.99%, compared to EVO's ROE of -0.17%. Regarding short-term risk, CGC is more volatile compared to EVO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check EVO's competition here
CGC vs COLL Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, COLL has a market cap of 1.2B. Regarding current trading prices, CGC is priced at $1.44, while COLL trades at $38.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas COLL's P/E ratio is 36.58. In terms of profitability, CGC's ROE is -0.99%, compared to COLL's ROE of +0.16%. Regarding short-term risk, CGC is more volatile compared to COLL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check COLL's competition here
CGC vs DVAX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, DVAX has a market cap of 1.2B. Regarding current trading prices, CGC is priced at $1.44, while DVAX trades at $10.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas DVAX's P/E ratio is -23.09. In terms of profitability, CGC's ROE is -0.99%, compared to DVAX's ROE of -0.09%. Regarding short-term risk, CGC is more volatile compared to DVAX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check DVAX's competition here
CGC vs PCRX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, PCRX has a market cap of 1.1B. Regarding current trading prices, CGC is priced at $1.44, while PCRX trades at $25.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas PCRX's P/E ratio is -9.22. In terms of profitability, CGC's ROE is -0.99%, compared to PCRX's ROE of -0.17%. Regarding short-term risk, CGC is more volatile compared to PCRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check PCRX's competition here
CGC vs CRON Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, CRON has a market cap of 991.8M. Regarding current trading prices, CGC is priced at $1.44, while CRON trades at $2.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas CRON's P/E ratio is 51.80. In terms of profitability, CGC's ROE is -0.99%, compared to CRON's ROE of +0.02%. Regarding short-term risk, CGC is more volatile compared to CRON. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check CRON's competition here
CGC vs PETQ Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, PETQ has a market cap of 919.2M. Regarding current trading prices, CGC is priced at $1.44, while PETQ trades at $30.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas PETQ's P/E ratio is 83.73. In terms of profitability, CGC's ROE is -0.99%, compared to PETQ's ROE of +0.12%. Regarding short-term risk, CGC is more volatile compared to PETQ. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check PETQ's competition here
CGC vs EMBC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, EMBC has a market cap of 834M. Regarding current trading prices, CGC is priced at $1.44, while EMBC trades at $14.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas EMBC's P/E ratio is 10.04. In terms of profitability, CGC's ROE is -0.99%, compared to EMBC's ROE of -0.11%. Regarding short-term risk, CGC is more volatile compared to EMBC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check EMBC's competition here
CGC vs SIGA Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SIGA has a market cap of 623M. Regarding current trading prices, CGC is priced at $1.44, while SIGA trades at $8.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SIGA's P/E ratio is 7.63. In terms of profitability, CGC's ROE is -0.99%, compared to SIGA's ROE of +0.41%. Regarding short-term risk, CGC is more volatile compared to SIGA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SIGA's competition here
CGC vs SNDL Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SNDL has a market cap of 617.8M. Regarding current trading prices, CGC is priced at $1.44, while SNDL trades at $2.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SNDL's P/E ratio is -8.89. In terms of profitability, CGC's ROE is -0.99%, compared to SNDL's ROE of -0.09%. Regarding short-term risk, CGC is more volatile compared to SNDL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SNDL's competition here
CGC vs ORGO Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ORGO has a market cap of 592.4M. Regarding current trading prices, CGC is priced at $1.44, while ORGO trades at $4.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ORGO's P/E ratio is -33.36. In terms of profitability, CGC's ROE is -0.99%, compared to ORGO's ROE of -0.03%. Regarding short-term risk, CGC is more volatile compared to ORGO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ORGO's competition here
CGC vs BDSI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, BDSI has a market cap of 577.1M. Regarding current trading prices, CGC is priced at $1.44, while BDSI trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas BDSI's P/E ratio is 6.82. In terms of profitability, CGC's ROE is -0.99%, compared to BDSI's ROE of +0.57%. Regarding short-term risk, CGC is more volatile compared to BDSI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check BDSI's competition here
CGC vs EBS Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, EBS has a market cap of 491.4M. Regarding current trading prices, CGC is priced at $1.44, while EBS trades at $9.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas EBS's P/E ratio is 3.52. In terms of profitability, CGC's ROE is -0.99%, compared to EBS's ROE of +0.27%. Regarding short-term risk, CGC is more volatile compared to EBS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check EBS's competition here
CGC vs EOLS Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, EOLS has a market cap of 480.6M. Regarding current trading prices, CGC is priced at $1.44, while EOLS trades at $7.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas EOLS's P/E ratio is -7.66. In terms of profitability, CGC's ROE is -0.99%, compared to EOLS's ROE of +17.91%. Regarding short-term risk, CGC is more volatile compared to EOLS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check EOLS's competition here
CGC vs ESPR Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ESPR has a market cap of 433.3M. Regarding current trading prices, CGC is priced at $1.44, while ESPR trades at $2.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ESPR's P/E ratio is -3.98. In terms of profitability, CGC's ROE is -0.99%, compared to ESPR's ROE of +0.32%. Regarding short-term risk, CGC is more volatile compared to ESPR. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ESPR's competition here
CGC vs KMDA Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, KMDA has a market cap of 405.1M. Regarding current trading prices, CGC is priced at $1.44, while KMDA trades at $7.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas KMDA's P/E ratio is 22.01. In terms of profitability, CGC's ROE is -0.99%, compared to KMDA's ROE of +0.07%. Regarding short-term risk, CGC is more volatile compared to KMDA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check KMDA's competition here
CGC vs AQST Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, AQST has a market cap of 385M. Regarding current trading prices, CGC is priced at $1.44, while AQST trades at $3.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas AQST's P/E ratio is -5.59. In terms of profitability, CGC's ROE is -0.99%, compared to AQST's ROE of +1.09%. Regarding short-term risk, CGC is more volatile compared to AQST. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check AQST's competition here
CGC vs ZYBT Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ZYBT has a market cap of 379.1M. Regarding current trading prices, CGC is priced at $1.44, while ZYBT trades at $8.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ZYBT's P/E ratio is 266.67. In terms of profitability, CGC's ROE is -0.99%, compared to ZYBT's ROE of +0.04%. Regarding short-term risk, CGC is less volatile compared to ZYBT. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check ZYBT's competition here
CGC vs ALIM Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ALIM has a market cap of 301.3M. Regarding current trading prices, CGC is priced at $1.44, while ALIM trades at $5.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ALIM's P/E ratio is 5.28. In terms of profitability, CGC's ROE is -0.99%, compared to ALIM's ROE of -0.24%. Regarding short-term risk, CGC is more volatile compared to ALIM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ALIM's competition here
CGC vs ACB Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ACB has a market cap of 294.7M. Regarding current trading prices, CGC is priced at $1.44, while ACB trades at $5.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ACB's P/E ratio is -130.97. In terms of profitability, CGC's ROE is -0.99%, compared to ACB's ROE of +0.00%. Regarding short-term risk, CGC is more volatile compared to ACB. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ACB's competition here
CGC vs LFCR Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, LFCR has a market cap of 283.9M. Regarding current trading prices, CGC is priced at $1.44, while LFCR trades at $7.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas LFCR's P/E ratio is -5.98. In terms of profitability, CGC's ROE is -0.99%, compared to LFCR's ROE of -2.53%. Regarding short-term risk, CGC is more volatile compared to LFCR. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check LFCR's competition here
CGC vs LNDC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, LNDC has a market cap of 263.6M. Regarding current trading prices, CGC is priced at $1.44, while LNDC trades at $8.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas LNDC's P/E ratio is -4.04. In terms of profitability, CGC's ROE is -0.99%, compared to LNDC's ROE of -10.27%. Regarding short-term risk, CGC is more volatile compared to LNDC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check LNDC's competition here
CGC vs TKNO Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TKNO has a market cap of 239.7M. Regarding current trading prices, CGC is priced at $1.44, while TKNO trades at $4.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TKNO's P/E ratio is -11.49. In terms of profitability, CGC's ROE is -0.99%, compared to TKNO's ROE of -0.27%. Regarding short-term risk, CGC is more volatile compared to TKNO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check TKNO's competition here
CGC vs TYHT Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TYHT has a market cap of 229.2M. Regarding current trading prices, CGC is priced at $1.44, while TYHT trades at $11.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TYHT's P/E ratio is -1.61. In terms of profitability, CGC's ROE is -0.99%, compared to TYHT's ROE of -0.57%. Regarding short-term risk, CGC is more volatile compared to TYHT. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check TYHT's competition here
CGC vs OGI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, OGI has a market cap of 218.2M. Regarding current trading prices, CGC is priced at $1.44, while OGI trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas OGI's P/E ratio is 163.00. In terms of profitability, CGC's ROE is -0.99%, compared to OGI's ROE of +0.02%. Regarding short-term risk, CGC is more volatile compared to OGI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check OGI's competition here
CGC vs IRWD Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, IRWD has a market cap of 206.3M. Regarding current trading prices, CGC is priced at $1.44, while IRWD trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas IRWD's P/E ratio is -25.40. In terms of profitability, CGC's ROE is -0.99%, compared to IRWD's ROE of +0.03%. Regarding short-term risk, CGC is more volatile compared to IRWD. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check IRWD's competition here
CGC vs DERM Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, DERM has a market cap of 180.4M. Regarding current trading prices, CGC is priced at $1.44, while DERM trades at $7.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas DERM's P/E ratio is -20.00. In terms of profitability, CGC's ROE is -0.99%, compared to DERM's ROE of -0.49%. Regarding short-term risk, CGC is more volatile compared to DERM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check DERM's competition here
CGC vs REPH Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, REPH has a market cap of 177.4M. Regarding current trading prices, CGC is priced at $1.44, while REPH trades at $2.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas REPH's P/E ratio is -8.04. In terms of profitability, CGC's ROE is -0.99%, compared to REPH's ROE of -0.22%. Regarding short-term risk, CGC is more volatile compared to REPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check REPH's competition here
CGC vs SXTC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SXTC has a market cap of 171.7M. Regarding current trading prices, CGC is priced at $1.44, while SXTC trades at $1.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SXTC's P/E ratio is -0.64. In terms of profitability, CGC's ROE is -0.99%, compared to SXTC's ROE of +0.17%. Regarding short-term risk, CGC is more volatile compared to SXTC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SXTC's competition here
CGC vs BIOA Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, BIOA has a market cap of 161.7M. Regarding current trading prices, CGC is priced at $1.44, while BIOA trades at $4.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas BIOA's P/E ratio is -0.66. In terms of profitability, CGC's ROE is -0.99%, compared to BIOA's ROE of -0.25%. Regarding short-term risk, CGC is more volatile compared to BIOA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check BIOA's competition here
CGC vs THTX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, THTX has a market cap of 149.4M. Regarding current trading prices, CGC is priced at $1.44, while THTX trades at $3.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas THTX's P/E ratio is -17.11. In terms of profitability, CGC's ROE is -0.99%, compared to THTX's ROE of +0.38%. Regarding short-term risk, CGC is more volatile compared to THTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check THTX's competition here
CGC vs SCTL Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SCTL has a market cap of 116.1M. Regarding current trading prices, CGC is priced at $1.44, while SCTL trades at $1.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SCTL's P/E ratio is -7.86. In terms of profitability, CGC's ROE is -0.99%, compared to SCTL's ROE of -0.22%. Regarding short-term risk, CGC is more volatile compared to SCTL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SCTL's competition here
CGC vs PROC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, PROC has a market cap of 114M. Regarding current trading prices, CGC is priced at $1.44, while PROC trades at $1.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas PROC's P/E ratio is 1.53. In terms of profitability, CGC's ROE is -0.99%, compared to PROC's ROE of -2.22%. Regarding short-term risk, CGC is more volatile compared to PROC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check PROC's competition here
CGC vs OPTN Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, OPTN has a market cap of 97.2M. Regarding current trading prices, CGC is priced at $1.44, while OPTN trades at $9.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas OPTN's P/E ratio is -4.42. In terms of profitability, CGC's ROE is -0.99%, compared to OPTN's ROE of +0.64%. Regarding short-term risk, CGC is more volatile compared to OPTN. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check OPTN's competition here
CGC vs ZOM Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ZOM has a market cap of 95.3M. Regarding current trading prices, CGC is priced at $1.44, while ZOM trades at $0.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ZOM's P/E ratio is -1.62. In terms of profitability, CGC's ROE is -0.99%, compared to ZOM's ROE of -0.52%. Regarding short-term risk, CGC is more volatile compared to ZOM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ZOM's competition here
CGC vs CRDL Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, CRDL has a market cap of 94.2M. Regarding current trading prices, CGC is priced at $1.44, while CRDL trades at $1.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas CRDL's P/E ratio is -3.26. In terms of profitability, CGC's ROE is -0.99%, compared to CRDL's ROE of -2.33%. Regarding short-term risk, CGC is more volatile compared to CRDL. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check CRDL's competition here
CGC vs INCR Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, INCR has a market cap of 89.9M. Regarding current trading prices, CGC is priced at $1.44, while INCR trades at $1.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas INCR's P/E ratio is -4.02. In terms of profitability, CGC's ROE is -0.99%, compared to INCR's ROE of -0.15%. Regarding short-term risk, CGC is less volatile compared to INCR. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check INCR's competition here
CGC vs GRVI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, GRVI has a market cap of 88.9M. Regarding current trading prices, CGC is priced at $1.44, while GRVI trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas GRVI's P/E ratio is 26.05. In terms of profitability, CGC's ROE is -0.99%, compared to GRVI's ROE of +0.28%. Regarding short-term risk, CGC is more volatile compared to GRVI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check GRVI's competition here
CGC vs ASRT Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ASRT has a market cap of 75.6M. Regarding current trading prices, CGC is priced at $1.44, while ASRT trades at $0.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ASRT's P/E ratio is -1.75. In terms of profitability, CGC's ROE is -0.99%, compared to ASRT's ROE of -0.38%. Regarding short-term risk, CGC is more volatile compared to ASRT. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ASRT's competition here
CGC vs ZYNE Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ZYNE has a market cap of 70.1M. Regarding current trading prices, CGC is priced at $1.44, while ZYNE trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ZYNE's P/E ratio is -1.65. In terms of profitability, CGC's ROE is -0.99%, compared to ZYNE's ROE of -0.59%. Regarding short-term risk, CGC is more volatile compared to ZYNE. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check ZYNE's competition here
CGC vs IXHL Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, IXHL has a market cap of 68M. Regarding current trading prices, CGC is priced at $1.44, while IXHL trades at $0.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas IXHL's P/E ratio is -0.60. In terms of profitability, CGC's ROE is -0.99%, compared to IXHL's ROE of -3.57%. Regarding short-term risk, CGC is less volatile compared to IXHL. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check IXHL's competition here
CGC vs QNTM Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, QNTM has a market cap of 67.5M. Regarding current trading prices, CGC is priced at $1.44, while QNTM trades at $17.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas QNTM's P/E ratio is -1.55. In terms of profitability, CGC's ROE is -0.99%, compared to QNTM's ROE of -2.90%. Regarding short-term risk, CGC is more volatile compared to QNTM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check QNTM's competition here
CGC vs SSIC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SSIC has a market cap of 66.7M. Regarding current trading prices, CGC is priced at $1.44, while SSIC trades at $10.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SSIC's P/E ratio is 11.93. In terms of profitability, CGC's ROE is -0.99%, compared to SSIC's ROE of +0.09%. Regarding short-term risk, CGC is more volatile compared to SSIC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SSIC's competition here
CGC vs KALA Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, KALA has a market cap of 61.6M. Regarding current trading prices, CGC is priced at $1.44, while KALA trades at $8.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas KALA's P/E ratio is -1.47. In terms of profitability, CGC's ROE is -0.99%, compared to KALA's ROE of -6.86%. Regarding short-term risk, CGC is more volatile compared to KALA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check KALA's competition here
CGC vs VLNS Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, VLNS has a market cap of 61.5M. Regarding current trading prices, CGC is priced at $1.44, while VLNS trades at $0.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas VLNS's P/E ratio is -1.03. In terms of profitability, CGC's ROE is -0.99%, compared to VLNS's ROE of N/A. Regarding short-term risk, CGC is more volatile compared to VLNS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check VLNS's competition here
CGC vs DRRX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, DRRX has a market cap of 60.2M. Regarding current trading prices, CGC is priced at $1.44, while DRRX trades at $1.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas DRRX's P/E ratio is -4.51. In terms of profitability, CGC's ROE is -0.99%, compared to DRRX's ROE of -0.71%. Regarding short-term risk, CGC is more volatile compared to DRRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check DRRX's competition here
CGC vs JUPW Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, JUPW has a market cap of 49.3M. Regarding current trading prices, CGC is priced at $1.44, while JUPW trades at $1.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas JUPW's P/E ratio is -2.41. In terms of profitability, CGC's ROE is -0.99%, compared to JUPW's ROE of -0.32%. Regarding short-term risk, CGC is less volatile compared to JUPW. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check JUPW's competition here
CGC vs CPIX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, CPIX has a market cap of 48.8M. Regarding current trading prices, CGC is priced at $1.44, while CPIX trades at $3.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas CPIX's P/E ratio is -14.82. In terms of profitability, CGC's ROE is -0.99%, compared to CPIX's ROE of -0.11%. Regarding short-term risk, CGC is more volatile compared to CPIX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check CPIX's competition here
CGC vs RMTI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, RMTI has a market cap of 44.8M. Regarding current trading prices, CGC is priced at $1.44, while RMTI trades at $1.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas RMTI's P/E ratio is -18.57. In terms of profitability, CGC's ROE is -0.99%, compared to RMTI's ROE of -0.07%. Regarding short-term risk, CGC is less volatile compared to RMTI. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check RMTI's competition here
CGC vs EGRX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, EGRX has a market cap of 41.4M. Regarding current trading prices, CGC is priced at $1.44, while EGRX trades at $3.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas EGRX's P/E ratio is 3.75. In terms of profitability, CGC's ROE is -0.99%, compared to EGRX's ROE of +0.17%. Regarding short-term risk, CGC is more volatile compared to EGRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check EGRX's competition here
CGC vs QLI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, QLI has a market cap of 38.7M. Regarding current trading prices, CGC is priced at $1.44, while QLI trades at $5.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas QLI's P/E ratio is -4.92. In terms of profitability, CGC's ROE is -0.99%, compared to QLI's ROE of -0.16%. Regarding short-term risk, CGC is more volatile compared to QLI. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check QLI's competition here
CGC vs SCYX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SCYX has a market cap of 35.4M. Regarding current trading prices, CGC is priced at $1.44, while SCYX trades at $0.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SCYX's P/E ratio is -2.11. In terms of profitability, CGC's ROE is -0.99%, compared to SCYX's ROE of -0.37%. Regarding short-term risk, CGC is more volatile compared to SCYX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SCYX's competition here
CGC vs HEXO Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, HEXO has a market cap of 31.2M. Regarding current trading prices, CGC is priced at $1.44, while HEXO trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas HEXO's P/E ratio is -0.26. In terms of profitability, CGC's ROE is -0.99%, compared to HEXO's ROE of -2.06%. Regarding short-term risk, CGC is more volatile compared to HEXO. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check HEXO's competition here
CGC vs COSM Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, COSM has a market cap of 24.4M. Regarding current trading prices, CGC is priced at $1.44, while COSM trades at $0.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas COSM's P/E ratio is -0.79. In terms of profitability, CGC's ROE is -0.99%, compared to COSM's ROE of -0.55%. Regarding short-term risk, CGC is more volatile compared to COSM. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check COSM's competition here
CGC vs CYTH Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, CYTH has a market cap of 23.6M. Regarding current trading prices, CGC is priced at $1.44, while CYTH trades at $0.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas CYTH's P/E ratio is -0.80. In terms of profitability, CGC's ROE is -0.99%, compared to CYTH's ROE of +3.20%. Regarding short-term risk, CGC is more volatile compared to CYTH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check CYTH's competition here
CGC vs ACRX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, ACRX has a market cap of 14.6M. Regarding current trading prices, CGC is priced at $1.44, while ACRX trades at $0.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas ACRX's P/E ratio is -0.31. In terms of profitability, CGC's ROE is -0.99%, compared to ACRX's ROE of -1.51%. Regarding short-term risk, CGC is less volatile compared to ACRX. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check ACRX's competition here
CGC vs AYTU Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, AYTU has a market cap of 14.2M. Regarding current trading prices, CGC is priced at $1.44, while AYTU trades at $2.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas AYTU's P/E ratio is -1.54. In terms of profitability, CGC's ROE is -0.99%, compared to AYTU's ROE of +0.05%. Regarding short-term risk, CGC is more volatile compared to AYTU. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check AYTU's competition here
CGC vs PRPH Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, PRPH has a market cap of 13.9M. Regarding current trading prices, CGC is priced at $1.44, while PRPH trades at $0.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas PRPH's P/E ratio is -0.16. In terms of profitability, CGC's ROE is -0.99%, compared to PRPH's ROE of -2.30%. Regarding short-term risk, CGC is more volatile compared to PRPH. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check PRPH's competition here
CGC vs GELS Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, GELS has a market cap of 13.3M. Regarding current trading prices, CGC is priced at $1.44, while GELS trades at $1.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas GELS's P/E ratio is -3.91. In terms of profitability, CGC's ROE is -0.99%, compared to GELS's ROE of -0.07%. Regarding short-term risk, CGC is more volatile compared to GELS. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check GELS's competition here
CGC vs TXMD Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TXMD has a market cap of 12.8M. Regarding current trading prices, CGC is priced at $1.44, while TXMD trades at $1.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TXMD's P/E ratio is -22.20. In terms of profitability, CGC's ROE is -0.99%, compared to TXMD's ROE of -0.02%. Regarding short-term risk, CGC is more volatile compared to TXMD. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check TXMD's competition here
CGC vs TLPH Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, TLPH has a market cap of 12M. Regarding current trading prices, CGC is priced at $1.44, while TLPH trades at $0.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas TLPH's P/E ratio is -1.50. In terms of profitability, CGC's ROE is -0.99%, compared to TLPH's ROE of -1.51%. Regarding short-term risk, CGC is less volatile compared to TLPH. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check TLPH's competition here
CGC vs FLGC Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, FLGC has a market cap of 11.9M. Regarding current trading prices, CGC is priced at $1.44, while FLGC trades at $20.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas FLGC's P/E ratio is -0.59. In terms of profitability, CGC's ROE is -0.99%, compared to FLGC's ROE of -2.98%. Regarding short-term risk, CGC is more volatile compared to FLGC. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check FLGC's competition here
CGC vs AGRX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, AGRX has a market cap of 10.4M. Regarding current trading prices, CGC is priced at $1.44, while AGRX trades at $1.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas AGRX's P/E ratio is -0.89. In terms of profitability, CGC's ROE is -0.99%, compared to AGRX's ROE of +0.66%. Regarding short-term risk, CGC is more volatile compared to AGRX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check AGRX's competition here
CGC vs BFRI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, BFRI has a market cap of 9.8M. Regarding current trading prices, CGC is priced at $1.44, while BFRI trades at $0.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas BFRI's P/E ratio is -0.51. In terms of profitability, CGC's ROE is -0.99%, compared to BFRI's ROE of -11.51%. Regarding short-term risk, CGC is less volatile compared to BFRI. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check BFRI's competition here
CGC vs BFRIW Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, BFRIW has a market cap of 8.8M. Regarding current trading prices, CGC is priced at $1.44, while BFRIW trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas BFRIW's P/E ratio is -0.09. In terms of profitability, CGC's ROE is -0.99%, compared to BFRIW's ROE of -11.51%. Regarding short-term risk, CGC is more volatile compared to BFRIW. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check BFRIW's competition here
CGC vs NLTX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, NLTX has a market cap of 8.2M. Regarding current trading prices, CGC is priced at $1.44, while NLTX trades at $3.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas NLTX's P/E ratio is -0.28. In terms of profitability, CGC's ROE is -0.99%, compared to NLTX's ROE of -0.45%. Regarding short-term risk, CGC is more volatile compared to NLTX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check NLTX's competition here
CGC vs EVOK Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, EVOK has a market cap of 8.1M. Regarding current trading prices, CGC is priced at $1.44, while EVOK trades at $5.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas EVOK's P/E ratio is -4.16. In terms of profitability, CGC's ROE is -0.99%, compared to EVOK's ROE of -0.99%. Regarding short-term risk, CGC is more volatile compared to EVOK. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check EVOK's competition here
CGC vs SNOA Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, SNOA has a market cap of 7.9M. Regarding current trading prices, CGC is priced at $1.44, while SNOA trades at $4.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas SNOA's P/E ratio is -2.19. In terms of profitability, CGC's ROE is -0.99%, compared to SNOA's ROE of -0.76%. Regarding short-term risk, CGC is more volatile compared to SNOA. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check SNOA's competition here
CGC vs LCI Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, LCI has a market cap of 7.4M. Regarding current trading prices, CGC is priced at $1.44, while LCI trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas LCI's P/E ratio is -0.04. In terms of profitability, CGC's ROE is -0.99%, compared to LCI's ROE of +1.66%. Regarding short-term risk, CGC is less volatile compared to LCI. This indicates potentially lower risk in terms of short-term price fluctuations for CGC.Check LCI's competition here
CGC vs BGXX Comparison August 2025
CGC plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CGC stands at 345.3M. In comparison, BGXX has a market cap of 7.3M. Regarding current trading prices, CGC is priced at $1.44, while BGXX trades at $0.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CGC currently has a P/E ratio of -0.48, whereas BGXX's P/E ratio is -0.76. In terms of profitability, CGC's ROE is -0.99%, compared to BGXX's ROE of -0.35%. Regarding short-term risk, CGC is more volatile compared to BGXX. This indicates potentially higher risk in terms of short-term price fluctuations for CGC.Check BGXX's competition here